Rik Ossenkoppele

Research interests

Publications

• Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

  JAMA · 2024 · 10.1001/jama.2024.13855

• Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

  Nature Medicine · 2024 · 10.1038/s41591-024-02869-z

• Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

  JAMA Neurology · 2023 · 10.1001/jamaneurol.2022.5272

• Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

  The Lancet Neurology · 2022 · 10.1016/s1474-4422(22)00168-5

• Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

  JAMA Neurology · 2022 · https://doi.org/10.1001/jamaneurol.2021.5216

• Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

  Nature Medicine · 2022 · 10.1038/s41591-022-02049-x

• Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

  JAMA Neurology · 2021 · 10.1001/jamaneurol.2021.1858

• Four distinct trajectories of tau deposition identified in Alzheimer’s disease

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01309-6

• The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

  Nature reviews. Neuroscience · 2021 · 10.1038/s41583-021-00533-w

• Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

  Alzheimer s Research & Therapy · 2020 · 10.1186/s13195-020-00682-7

• Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

  The Lancet Neurology · 2020 · https://doi.org/10.1016/s1474-4422(20)30314-8

• Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

  Nature Communications · 2020 · 10.1038/s41467-019-14159-1

• Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

  Science Advances · 2020 · 10.1126/sciadv.aaz2387

• Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease

  Brain · 2020 · 10.1093/brain/awaa068

• Amyloid-β-independent regulators of tau pathology in Alzheimer disease

  Nature reviews. Neuroscience · 2019 · 10.1038/s41583-019-0240-3

• Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

  Neurology · 2019 · 10.1212/wnl.0000000000006875

• Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

  JAMA · 2018 · 10.1001/jama.2018.12917

• Clinicopathological correlations in behavioural variant frontotemporal dementia

  Brain · 2017 · 10.1093/brain/awx254

• Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

  Brain · 2016 · https://doi.org/10.1093/brain/aww027

• PET Imaging of Tau Deposition in the Aging Human Brain

  Neuron · 2016 · https://doi.org/10.1016/j.neuron.2016.01.028

• Atrophy patterns in early clinical stages across distinct phenotypes of A lzheimer's disease

  Human Brain Mapping · 2015 · 10.1002/hbm.22927

• Prevalence of Amyloid PET Positivity in Dementia Syndromes

  JAMA · 2015 · https://doi.org/10.1001/jama.2015.4669

• The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials

  Ageing Research Reviews · 2015 · 10.1016/j.arr.2015.11.005

• The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features

  Brain · 2015 · 10.1093/brain/awv191

• Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

  JAMA · 2015 · https://doi.org/10.1001/jama.2015.4668

Current projects

No projects listed.